|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.248 SEK | +2.13% |
|
-0.79% | -36.65% |
| 05-06 | IRLAB Q1 operating result swings to profit of SEK 10.7 mln | RE |
| 05-06 | Irlab reports growth in revenue and operating profit | FW |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | - | 208M | 61.14M | 5.68M | 94.63M | |||||
Other Revenues, Total | 300K | - | - | - | - | |||||
Total Revenues | 300K | 208M | 61.14M | 5.68M | 94.63M | |||||
Cost of Goods Sold, Total | 65.63M | 81.74M | 126M | 128M | 136M | |||||
Gross Profit | -65.33M | 126M | -64.77M | -123M | -41.66M | |||||
Selling General & Admin Expenses, Total | 23.97M | 31.02M | 42.48M | 53.08M | 46.18M | |||||
Depreciation & Amortization - (IS) | 2.26M | 3.47M | 4.78M | 4.32M | 4.58M | |||||
Other Operating Expenses | -96K | 38.97M | -27K | -42K | -19.46M | |||||
Other Operating Expenses, Total | 26.13M | 73.47M | 47.23M | 57.36M | 31.31M | |||||
Operating Income | -91.46M | 52.58M | -112M | -180M | -72.97M | |||||
Interest Expense, Total | -195K | -370K | -297K | -199K | -10.48M | |||||
Interest And Investment Income | 1K | 1K | - | 3.12M | 2.46M | |||||
Net Interest Expenses | -194K | -369K | -297K | 2.93M | -8.02M | |||||
Currency Exchange Gains (Loss) | - | -426K | -1.11M | -676K | -2.14M | |||||
Other Non Operating Income (Expenses) | -1K | - | - | 1K | - | |||||
EBT, Excl. Unusual Items | -91.65M | 51.78M | -113M | -178M | -83.13M | |||||
Asset Writedown | - | - | - | - | - | |||||
Insurance Settlements | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | -91.65M | 51.78M | -113M | -178M | -83.13M | |||||
Income Tax Expense | - | - | - | - | - | |||||
Earnings From Continuing Operations | -91.65M | 51.78M | -113M | -178M | -83.13M | |||||
Net Income to Company | -91.65M | 51.78M | -113M | -178M | -83.13M | |||||
Minority Interest | - | - | - | - | - | |||||
Net Income - (IS) | -91.65M | 51.78M | -113M | -178M | -83.13M | |||||
Net Income to Common Incl Extra Items | -91.65M | 51.78M | -113M | -178M | -83.13M | |||||
Net Income to Common Excl. Extra Items | -91.65M | 51.78M | -113M | -178M | -83.13M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -1.92 | 1 | -2.19 | -3.43 | -1.6 | |||||
Basic EPS - Continuing Operations | -1.92 | 1 | -2.19 | -3.43 | -1.6 | |||||
Basic Weighted Average Shares Outstanding | 47.68M | 51.75M | 51.83M | 51.87M | 51.87M | |||||
Net EPS - Diluted | -1.92 | 1 | -2.19 | -3.43 | -1.6 | |||||
Diluted EPS - Continuing Operations | -1.92 | 1 | -2.19 | -3.43 | -1.6 | |||||
Diluted Weighted Average Shares Outstanding | 47.68M | 51.75M | 51.83M | 51.87M | 51.87M | |||||
Normalized Basic EPS | -1.2 | 0.63 | -1.37 | -2.14 | -1 | |||||
Normalized Diluted EPS | -1.2 | 0.63 | -1.37 | -2.14 | -1 | |||||
Supplemental Items | ||||||||||
EBITDA | -91.12M | 53.07M | -111M | -179M | -72.08M | |||||
EBITA | -91.46M | 52.58M | -112M | -180M | -72.97M | |||||
EBIT | -91.46M | 52.58M | -112M | -180M | -72.97M | |||||
EBITDAR | -91M | 53.26M | - | - | - | |||||
Total Revenues (As Reported) | 404K | 208M | 61.28M | 5.72M | 114M | |||||
Effective Tax Rate - (Ratio) | - | - | - | - | - | |||||
Deferred Domestic Taxes | - | - | - | - | - | |||||
Total Deferred Taxes | - | - | - | - | - | |||||
Normalized Net Income | -57.28M | 32.36M | -70.88M | -111M | -51.96M | |||||
Interest on Long-Term Debt | 193K | 367K | - | - | - | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 75.99M | 130M | 146M | 151M | 164M | |||||
Net Rental Expense, Total | 130K | 187K | - | - | - | |||||
Imputed Operating Lease Interest Expense | 54.3K | 116K | - | - | - | |||||
Imputed Operating Lease Depreciation | 75.7K | 70.8K | - | - | - |
- Stock Market
- Equities
- IRLAB A Stock
- Financials IRLAB Therapeutics AB
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















